PGR and neoplasm: As evidenced by the best change in tumor size and corresponding ORR, all prognostic subgroups received benefit from the addition of abemaciclib to AI, with the largest effects observed in subgroups of patients with liver metastases, PgR-negative tumors, high-grade tumors, or TFI < 36 months (Fig. 2b).